Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2002-05-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00037700
Juvenile Rheumatoid Arthritis
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00037648
A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
Phase 4
Completed
- Conditions
- HyperparathyroidismParathyroid Neoplasms
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT00037518
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
Phase 3
Completed
- Conditions
- Secondary HyperparathyroidismEnd Stage Renal Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00037635
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT00035620
Chemotherapy Related Anemia
Phase 2
Completed
- Conditions
- AnemiaNon-Myeloid Malignancies
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 120
- Registration Number
- NCT00035607
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 928
- Registration Number
- NCT00035594
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Non-Small Cell Lung CancerNeoplasm MetastasisLung Cancer
- First Posted Date
- 2002-04-26
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 194
- Registration Number
- NCT00034346
A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex
Not Applicable
Completed
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT00002281
- Locations
- 🇺🇸
UCLA Med Ctr, Los Angeles, California, United States
An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00002255
- Locations
- 🇺🇸
UCLA Med Ctr, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath